Background – To evaluate the feasibility, efficacy, and toxicity of the combination of carboplatin plus docetaxel as a first-line treatment in advanced epithelial ovarian cancer
We present the data from 105 patients with primary epithelial ovarian dancer, who received up to 6 c...
Carboplatin/paclitaxel is the standard first-line chemotherapy for patients with advanced ovarian ca...
A combination of carboplatin (CBDCA) and paclitaxel (TAX) is the standard treatment in advanced ovar...
A prospective, non-randomized, multicentre, open, dose-finding study of a carboplatin-docetaxel (C-D...
The docetaxel-carboplatin combination is active and well tolerated in patients with epithelial ovari...
The feasibility of sequential carboplatin followed by docetaxel-based therapy for untreated ovarian ...
The feasibility of sequential carboplatin followed by docetaxel-based therapy for untreated ovarian ...
Docetaxel is being explored as an alternative to paclitaxel in the treatment of ovarian cancer for s...
Despite considerable progress over the past two decades in the management of advanced ovarian cancer...
OBJECTIVE: To evaluate and compare efficacy of docetaxel and paclitaxel combining with carboplatin i...
Background: Chemotherapy with a platinum agent and a taxane (paclitaxel) is considered the standard ...
Background: Chemotherapy with a platinum agent and a taxane (paclitaxel) is considered the standard ...
The objective of this study was to compare the safety and efficacy of carboplatin plus epirubicin an...
In the mid 1990s, the incorporation of paclitaxel into platinum-based therapy for ovarian cancer mar...
In patients with ovarian cancer relapsing at least 6 months after end of primary treatment, the addi...
We present the data from 105 patients with primary epithelial ovarian dancer, who received up to 6 c...
Carboplatin/paclitaxel is the standard first-line chemotherapy for patients with advanced ovarian ca...
A combination of carboplatin (CBDCA) and paclitaxel (TAX) is the standard treatment in advanced ovar...
A prospective, non-randomized, multicentre, open, dose-finding study of a carboplatin-docetaxel (C-D...
The docetaxel-carboplatin combination is active and well tolerated in patients with epithelial ovari...
The feasibility of sequential carboplatin followed by docetaxel-based therapy for untreated ovarian ...
The feasibility of sequential carboplatin followed by docetaxel-based therapy for untreated ovarian ...
Docetaxel is being explored as an alternative to paclitaxel in the treatment of ovarian cancer for s...
Despite considerable progress over the past two decades in the management of advanced ovarian cancer...
OBJECTIVE: To evaluate and compare efficacy of docetaxel and paclitaxel combining with carboplatin i...
Background: Chemotherapy with a platinum agent and a taxane (paclitaxel) is considered the standard ...
Background: Chemotherapy with a platinum agent and a taxane (paclitaxel) is considered the standard ...
The objective of this study was to compare the safety and efficacy of carboplatin plus epirubicin an...
In the mid 1990s, the incorporation of paclitaxel into platinum-based therapy for ovarian cancer mar...
In patients with ovarian cancer relapsing at least 6 months after end of primary treatment, the addi...
We present the data from 105 patients with primary epithelial ovarian dancer, who received up to 6 c...
Carboplatin/paclitaxel is the standard first-line chemotherapy for patients with advanced ovarian ca...
A combination of carboplatin (CBDCA) and paclitaxel (TAX) is the standard treatment in advanced ovar...